Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 8/20 | 0.57 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.48 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13957692 | 1.00 | ACE (0.57) | ACECHEK1JAK2POLBAPOBEC3A | |
| SCHEMBL14569615 | 0.87 | ACE (0.47) | ACECHEK1JAK2POLBAPOBEC3A | |
| SCHEMBL12013249 | 0.86 | ACE (0.46) | ACECHEK1JAK2 | |
| SCHEMBL14558076 | 0.86 | ACE (0.46) | ACECHEK1JAK2POLBAPOBEC3A | |
| SCHEMBL14558517 | 0.86 | ACE (0.46) | ACECHEK1JAK2 | |
| SCHEMBL7735074 | 0.86 | ACE (0.46) | ACECHEK1JAK2POLBAPOBEC3A | |
| SCHEMBL16624032 | 0.80 | NR1D1 (0.56) | ACE | |
| SCHEMBL12871199 | 0.80 | POLB (0.55) | ACEPOLBTDP1 | |
| SCHEMBL13971489 | 0.78 | ACE (0.54) | ACECHEK1JAK2POLBAPOBEC3A | |
| SCHEMBL3154327 | 0.78 | ACE (0.54) | ACECHEK1JAK2POLBAPOBEC3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200206196-A1 | Antiviral Drugs | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2020-07-02 | — | — | US | disclosed |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| EP-0901465-B1 | COMPOUNDS WITH ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE ACTIVITIES | ITALFARMACO SPA (IT) | 2000-09-27 | — | — | EP | disclosed |
| US-6034096-A | Compounds with anti-inflammatory and immunosuppressive activities | ITALFARMACO S.P.A. (IT) | 2000-03-07 | — | — | US | disclosed |
| EP-0901465-A1 | COMPOUNDS WITH ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE ACTIVITIES | ITALFARMACO S.p.A. (IT) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997043251-A1 | COMPOUNDS WITH ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE ACTIVITIES | ITALFARMACO S.P.A. (IT) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | ACE 2987/4885CHEK1 1033/4885JAK2 3011/4885 |
| US-20200206196-A1 | Antiviral Drugs | ACE2, MAVS, EIF2AK2 | ACE 4/4885CHEK1 954/4885JAK2 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.